Tablet composition with a prolonged release of tamsulosin

Details Tablet composition with a prolonged release of tamsulosin Tablet composition with a prolonged release of tamsulosin

2007-05-17

2011-10-04

Alstrum Acevedo, James H (Department: 1616)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Nitrogen containing other than solely as a nitrogen in an...

C514S960000, C514S961000, C514S964000, C424S408000, C424S464000, C424S468000

Reexamination Certificate

active

08030355

ABSTRACT:
A tamsulosin controlled release tablet is formed using a water-swellable matrix-forming composition as a release controlling mechanism. The matrix forming composition comprises (i) a pH-sensitive swellable hydrophilic polymer, which is a cross-linked polyacrylic acid polymer, and (ii) a pH-insensitive swellable hydrophilic polymer. The tablet optionally contains a water insoluble binder as well.

REFERENCES:
patent: 4217305 (1980-08-01), Imai et al.
patent: 4703063 (1987-10-01), Imai et al.
patent: 4731478 (1988-03-01), Niigata et al.
patent: 4772475 (1988-09-01), Fukui et al.
patent: 4868216 (1989-09-01), Imai et al.
patent: 4895841 (1990-01-01), Sugimoto et al.
patent: 4966768 (1990-10-01), Michelucci et al.
patent: 6177430 (2001-01-01), Thompson et al.
patent: 6287599 (2001-09-01), Burnside et al.
patent: 6335467 (2002-01-01), Englert et al.
patent: 6368628 (2002-04-01), Seth
patent: 6528685 (2003-03-01), Cohen et al.
patent: 6835853 (2004-12-01), Hoorn et al.
patent: 6965051 (2005-11-01), Hoorn et al.
patent: 7018658 (2006-03-01), Platteeuw
patent: 2003/0147955 (2003-08-01), Platteeuw et al.
patent: 2004/0096502 (2004-05-01), Platteeuw
patent: 2005/0100602 (2005-05-01), Sako et al.
patent: 2005/0100603 (2005-05-01), Sako et al.
patent: 2008/0075775 (2008-03-01), Gan et al.
patent: 0 034 432 (1981-08-01), None
patent: 0 257 787 (1988-03-01), None
patent: 0 186 087 (1989-08-01), None
patent: 0 194 838 (1993-09-01), None
patent: 0 533 297 (1997-11-01), None
patent: 0 309 157 (2000-05-01), None
patent: WO 94/06414 (1994-03-01), None
patent: WO 00/27364 (2000-05-01), None
patent: WO 2004/078212 (2004-09-01), None
NDA 20-579, FDA Office of Clinical Pharmacology and Biopharmaceutics Review, pp. 1-6, 1997.
Flowmax, MIMMS Abbreviated Prescribing Information, MIMMS Australia, 1996-2002.
Presentation entitled: “In Vivo Performance of Hydrophilic Matrix Tablets Utilizing HPMC: Case Studies” by Tim D. Cabelka, Ph.D. and Thomas D. Reynolds, Ph.D., The Dow Chemical Company, Oct. 17, 2000.
FDA—FOIA Labeling Information for Flomax®, 2001.
Dunn CJ, Matheson a and Faulds DM. “Tamsulosin A review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms.”Drugs Aging2002; 19; 135-161.
Dutkiewics S. “Efficacy and tolerability of drugs for treatment of benign prostatic hyperphasia.”Int Urology and Nephrology2001; 32; 423-432.
Harada K. and Fujimara A. “Clinical pharmacology of 1-A selective and nonselective 1-blockers.”BJU International2000; 86; 31-35.
Lyseng-Williamson KA, Jarvis B and Wagstaff AJ “Tamsulosin an update of its role in the management of lower urinary tract symptoms.”Drugs2002; 62; 135-167.
Michel MC, Neumann HG, Mehlburger L, Schumacher H and Goepel M. “Does the time for administration (morning or evening ” affect the tolerability or efficacy of tamsulosin?BJU International2001; 87; 31-34.
Soeishi Y, Korobi M, Kobayashi SI and Higuchi S. “Sensitive method for the determination of tamsulosin in human plasma using high-performance liquid chromotography with fluorescence detection”J of Chromotography1990; 553; 291-296.
Taguchi K. Schafers RF and Michel MC. “Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics.”Br J Clin Pharmacol.1998; 45; 49-55.
Van Hoogdalem EJ, Soeishi Y, Matsushima H and Higuchi S. “Disposition of the selective adrenoceptor antagonist tamsulosin in humans: Comparison with data from interspecies scaling.”J Pharm Sciences1997; 86; 1156-1161.
Rabasseda and Fitzpatrick, “Tamsulosin: The First Prostate-Selective alpha 1a-Adrenoceptor Antagonist for Treatment of Symptomatic Benign Prostatic Hyperplasia,” Drugs of Today, vol. 32, No. 3, 1996, pp. 259-268.

Affiliated with

Also associated with

Rating

Tablet composition with a prolonged release of tamsulosin does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tablet composition with a prolonged release of tamsulosin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tablet composition with a prolonged release of tamsulosin will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4261087